A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

It can worsen with age. However, its symptoms are less severe than those of Duchenne muscular dystrophy (DMD), which is more common. Becker muscular dystrophy (BMD) is a type of muscular ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

Results were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. "RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial.

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Wave Life Sciences’ experimental ...